peptide-based viral entry inhibitors (Ambrilia)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namepeptide-based viral entry inhibitors (Ambrilia)
Drug Alias Namepeptide E2 (Ambrilia)
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionVirus uptake inhibitors
TargetsUpdating
Therapy Area/IndicationsHepatitis C
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAmbrilia Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAmbrilia Biopharma Inc
Active IndicationsN/A
Inactive IndicationsHepatitis C

Other Information

ATC CodeN/A
Related LinksN/A